Navigation Links
Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications
Date:9/30/2008

ISO certification confirms implementation of quality systems in product

design and development, manufacture, and distribution for Cylex's

ImmuKnow(R) immune cell function assay

COLUMBIA, Md., Oct. 1 /PRNewswire/ -- Cylex has announced receipt of certification to ISO 13485:2003 and 9001:2000. The 13485:2003 certification includes compliance with the Canadian Medical Devices Conformity Assessment System (CMDCAS). These certifications signify compliance with internationally recognized standards in design, development, and manufacturing of medical products. The certifications were issued by TUV Rheinland of North America.

"This is a major achievement for the Company," stated Brad L. Stewart, president of Cylex. "ISO certification confirms that quality systems have been implemented in product design and development, manufacture, operations, shipping, and service and will support CE marking of Cylex products that will be labeled for in vitro diagnostic use for sale within the European Community. In addition, the certification confirms that Cylex meets global quality design and manufacturing requirements for Canada."

ISO 13485:2003 provides Cylex's customers with a "Quality Pledge" in regard to the Company's ongoing dedication to quality manufacturing, as well as demonstrating our readiness to take on the demanding challenges of building medical devices that are robust and reliable.

"In addition to the ISO 13485:2003 certificate, Cylex voluntarily elected to obtain certification to ISO 9001:2000 as well," Stewart went on to say. "We did this to demonstrate our commitment to customer focus, customer satisfaction, and continuous quality improvement. And I want to take this opportunity to clearly recognize all Cylex's employees for the dedication, focus, and hard work that has made this certification possible."

Certification to ISO standards is a baseline quality system requirement in many key markets for approval to sell a medical device and therefore supports the Company's plans to market its ImmuKnow immune cell function assay to customers around the world.

About ImmuKnow(R)

ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.

About Cylex, Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products intended to illuminate immunity. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. Cylex has received certification to ISO 13485:2003 and 9001:2000 for its quality system for "design and development, manufacture and distribution of in vitro diagnostic products related to immune function testing". The Company is based in Columbia, MD USA.


'/>"/>
SOURCE Cylex
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):